Introduction {#Sec1}
============

Homocystinuria is an inborn error in the metabolic pathways of sulfur-containing amino acids and is characterized by an increase in the level of toxic homocysteine (Hcy) in the serum^[@CR1]^. Mutations in cystathionine beta synthase (CBS), an enzyme present at the branch point between the trans-sulfuration and remethylation pathways, are the basic cause of homocysteinemia. The term "hyperhomocysteinemia" is also used to describe the elevated Hcy serum level due to other genetic (CBS-independent) and environmental factors^[@CR2]^. In a normal, healthy individual, the serum Hcy level is between 5--15 μM, but it can increase to 50 μM in mild cases and to 500 μM in severe cases of homocysteinemia (de Koning, Werstuck et al. 2003). This hyperhomocysteinemic condition is closely related to many disease conditions (Table [1](#Tab1){ref-type="table"}). It is believed that increased homocysteine levels lead to various cardiovascular complications (Table [1](#Tab1){ref-type="table"})^[@CR3],[@CR4]^ If the Hcy level is left uncontrolled, patients ultimately die of stroke^[@CR5]^. Further studies have also revealed that elevated plasma Hcy level is one of the key factors associated with neurodegeneration, diabetes, Down syndrome, neural tube defects, and megaloblastic anemia (see Table [1](#Tab1){ref-type="table"})^[@CR2],[@CR4],[@CR6]--[@CR9]^. Hyperhomocysteinemia has also been connected to various other clinical complications, including ectopic lentis, scoliosis, megaloblastic anemia, knocked knees, long limbs, and arachnodactyly, among others (Table [1](#Tab1){ref-type="table"})^[@CR4],[@CR10]--[@CR12]^. Recent advances have proven that there is a close link between hyperhomocystinuria and cancer (see Fig. [1](#Fig1){ref-type="fig"}). First, higher levels of plasma homocysteine have been observed cancer patients, and venous thromboembolism (VTE) is the second most common cause of death in cancer patients. Second, several polymorphisms in the enzymes involved in the Hcy detoxification pathways (the trans-sulfuration and remethylation) have close clinical ties to several cancer types^[@CR13]--[@CR23]^. Third, folate, which is pivotal for cell proliferation, has an inverse relation with Hcy. Fourth, Hcy has also been proposed as a potential tumor biomarker for a variety of cancers^[@CR24]^. In this review, we have systematically discussed these important key events in detail and revealed that defects in Hcy metabolism may lead to cancer. Future clinical perspectives have also been described.Table 1Homocysteinemia and its associated disordersComplicationAssociated diseasesReferencesCardiovascular diseasesThromboembolism^[@CR130],\ [@CR131]^Coronary artery^[@CR132]^Atherosclerosis^[@CR133],\ [@CR134]^Vascular dementia^[@CR135],\ [@CR136]^Congenital heart defects^[@CR137],\ [@CR138]^Stroke^[@CR139],\ [@CR140]^NeurodegenerationAlzheimer's^[@CR6]^Parkinson^[@CR141],\ [@CR142]^Schizophrenia^[@CR143],\ [@CR144]^Dementia^[@CR145],\ [@CR146]^Depression^[@CR147],\ [@CR148]^Diabetes---^[@CR149],\ [@CR150]^Down's syndrome---^[@CR151]^Megaloblastic anemia---^[@CR152]^Other diseasesNeural tube defects^[@CR55]^Nonsyndromic oral cleft^[@CR153]^Ectopic lentis^[@CR6],\ [@CR139],\ [@CR140]^Scoliosis^[@CR154]^Knocked knees^[@CR154]^Long limbs^[@CR154]^Arachnodactyly^[@CR154]^CancerRefer to Fig. [3](#Fig3){ref-type="fig"}Fig. 1Association between hyperhomocysteinemia and various cancer types

I (a) Low folate levels help build plasma Hcy {#Sec2}
=============================================

Homocysteine is a sulfur-containing, nonprotein, toxic amino acid found in the pathway for the interconversion of two amino acids: methionine and cysteine. Homocysteine is metabolized via two different pathways: remethylation and trans-sulfuration^[@CR25],[@CR26]^. When there is an excess of cellular methionine, the trans-sulfuration pathway plays a crucial role in Hcy metabolism, converting Hcy to cystathionine via CBS, which requires pyridoxal 5′-phosphate as a co-factor^[@CR25],[@CR27]^. When the cellular methionine level is low, Hcy is remethylated back to methionine in a betaine- or folate-dependent reaction. In the betaine-dependent pathway, the enzyme betaine-homocysteine S-methyltransferase (BHMT)^[@CR28],[@CR29]^ catalyzes the incorporation of a methyl group from betaine into homocysteine to form methionine. In the folate-dependent pathway, Hcy acquires a methyl group from N-5-methyltetrahydrofolate with the help of 5-methyltetrahydrofolate-homocysteine methyltransferase (MTR) (also known as methionine synthase). Methionine synthase requires vitamin B12 for its functionality, and the reaction also involves recycling of tetrahydrofolate (from N-5-methyltetrahydrofolate), which may eventually be used for nucleotide biosynthesis^[@CR30]^. Methionine synthase, therefore, couples the folate and Hcy metabolism pathways (Fig. [2](#Fig2){ref-type="fig"}). Since the generation of tetrahydrofolate depends on the input of exogenous folate for folate metabolism (as outlined in Fig. [2](#Fig2){ref-type="fig"}), low folate levels ultimately result in substrate limitation for methionine synthase, thereby affecting the remethylation pathway. Thus, low folate levels result in a high plasma Hcy concentration and vice versa.Fig. 2Folate metabolism is linked to the homocysteine metabolic pathway

Many factors that affect the folate level have also been found to disturb the Hcy level. For instance, diets deficient in folate, cobalamin, and vitamin B6^[@CR31]^ and use of anti-folate drugs (including anticonvulsants and other neurological drugs^[@CR32]^) directly increase the plasma Hcy level. Drugs that elevate the Hcy level (e.g., laxatives, diuretics, birth control pills, anti-inflammatory drugs, immune suppressants) also reduce the folic acid levels^[@CR33]--[@CR36]^. Other conditions, including alcohol consumption^[@CR13],[@CR18]^, smoking, diabetes, and psoriasis^[@CR37]^, among others, are responsible for reducing the plasma folate level by affecting the folate level. Therefore, it is important to take folate supplements to restore the depleted Hcy pool.

I (b) Low plasma folate levels lead to cancer predisposition {#Sec3}
============================================================

Folate is not only involved in nucleotide biosynthesis but also required for the conversion of deoxyuridine monophosphate (dUMP) into thymidine monophosphate^[@CR38]^. Under normal conditions, thymidylate synthetase (TYMS) converts dUMP into thymidine monophosphate using 5,10-methylenetetrahydrofolate (derived from folate) as a methyl group donor. If folate is limiting, dUMP accumulates because its key methyl donor, 5,10-methylenetetrahydrofolate, is absent. These conditions lead to an imbalance in the deoxyribonucleotide pool, and, consequently, there is excessive incorporation of uracil into DNA instead of thymine; this defect is normally repaired by the enzyme uracil DNA glycosylase, which removes the misincorporated uracil from the DNA strand^[@CR39]^. When the folate concentration is disturbed (due to increased Hcy levels) the DNA glycosylase fails to cope with the DNA repair burden. This situation leads to chromosomal damage, which may then lead malignant transformation in cells. Furthermore, excision repair of uracil residues 12 base pairs apart can lead to double strand breaks, which may increase DNA instability due to relaxed DNA supercoiling and chromosomal remodeling, both of which can cause an increase in malignant transformation. Chromosomal aberrations are also associated with inappropriate differentiation and morphology of lineage-specific cells, features often associated with tumors^[@CR40]^.

Low plasma folate levels are also linked to cancer is via DNA methylation. DNA methylation is an epigenetic modification that is critical for normal genome regulation and development. Indeed, it is Hcy that is recycled to methionine with the help of methionine synthase. DNA methylation is carried out with the help of a methyl donor, S-adenosyl-l-methionine (SAM), which is obtained from methionine via an ATP-dependent reaction catalyzed by S-adenomethyl synthetase^[@CR41]^. DNA methylation is jointly carried out by three types of DNA methyltransferases (DNMTs)---DNMT1, DNMT3a, and DNMT3b on SAM (Fig. [3](#Fig3){ref-type="fig"}). Since SAM is generated from 5-methyltetrahydrofolate (5′-MTHF) as shown in Fig. [3](#Fig3){ref-type="fig"}, low folate levels limit the substrate availability for methionine synthase, thereby resulting in DNA hypomethylation. DNA hypomethylation leads to decondensation of pericentromeric heterochromatin and the activation of retrotransposon elements^[@CR42]^. Global genomic hypomethylation has been found in many types of cancer, including prostate metastatic tumors, chronic lymphocytic tumors, and hepatocellular carcinoma. Regional hypomethylation of DNA sequences is also often observed during the early stages of tumorigenesis and in abnormal nonneoplastic tissue, such as hyperplasia^[@CR43]^.Fig. 3Low folate levels result in Hypomethylation

I (c) Cancer patients have high plasma Hcy levels {#Sec4}
=================================================

As mentioned in the earlier sections, there is an inverse relation between plasma Hcy and folate. In cancer patients, the plasma folate level is expected to be low because tumor cells must draw folate from the blood for de novo purine synthesis^[@CR44],[@CR45]^. Interestingly, as shown in Fig. [1](#Fig1){ref-type="fig"}, hyperhomocystinuria is associated with several types of cancer. It is also clear from the information in this figure that the causative relationship between homocysteine toxicity and cancer is independent of the organ/tissue and the type of cancer. Table [2](#Tab2){ref-type="table"} shows that all cancer types in the advanced stage exhibit high plasma Hcy levels, while there was no significant change in plasma Hcy levels in early stage cancer. Furthermore, once patients are subjected to surgery or chemotherapy, there is also a sharp increase in the plasma Hcy level, leading to a higher frequency of thromboembolic events. Because most commonly used clinical chemotherapeutic agents (such as alkylating agents, antimetabolites, methotrexate, hormones, and antagonists) are anti-folate drugs^[@CR46]^, their use causes a decrease in the plasma folic acid concentration. In another development, it has also been shown that older cancer patients are at a higher risk of developing hyperhomocysteinemia than are younger patients^[@CR47]^.Table 2Polymorphisms detected in genes involved in homocysteine metabolismGenePolymorphismsAmino acid changeCancer typeOR valuesReferencesMethylene-tetrahydrofolate reductase (MTHFR)677C- \> TA226VEndometrial carcinoma1.10^[@CR155]^Esophageal squamous cell carcinoma (SCC)1.47^[@CR156]^Breast cancer1.00^a^/1.12/1.00^a[@CR15],\ [@CR99],\ [@CR157]^Acute lymphocytic leukemia (ALL)0.99/0.23^[@CR87]^Prostate cancer0.78^[@CR158]^Colorectal cancer1.78/1.00^a^/0.76^[@CR85],\ [@CR159]--\ [@CR161]^1298A- \> CE443AProstate cancer0.58^[@CR79]^Acute myeloid leukemia0.33/1.00^[@CR87],\ [@CR162]^Endometrial cancer0.88^[@CR155]^1793G- \> AR1793EColorectal cancer0.17^[@CR163]^Acute myeloid leukemia1.00^[@CR162]^Methionine synthase reductase (MTRR)66A- \> GI22MLeukemia1.00^a[@CR164],\ [@CR165]^Colorectal cancer2.77/1.07^[@CR18],\ [@CR165],\ [@CR166]^Gastric cancer0.74/1.39^[@CR167],\ [@CR168]^Breast cancer4.45^[@CR169]^Methionine synthase (MTR)2756A- \> GD919GHead and neck carcinoma1.10^[@CR170]^Colorectal cancer1.03/0.65/2.04^[@CR161],\ [@CR170],\ [@CR171]^Lung cancer1.34^[@CR172]^Hepatocellular carcinoma1.01^[@CR170],\ [@CR173]^Cervical cancer0.27^[@CR14]^Glioblastoma multiforme1.00^a[@CR174]^Breast cancer1.00^a[@CR99]^Squamous cell carcinoma1.00^a[@CR98]^Gastric cancer1.06/1.35^[@CR168],\ [@CR170],\ [@CR175]^Pancreatic cancer1.08/3.35^[@CR170],\ [@CR176]^Methylene-tetrahydrofolate dehydrogenase (MTHFD1)1958G- \> AA653GGastric cancer2.05^[@CR102]^Leukemia0.80^[@CR177]^401G- \> AR134KGastric cancer1.43^[@CR102]^Leukemia0.89^[@CR177]^Ovarian cancer0.97^[@CR178]^Betaine-homocysteine methyltransferase (BHMT)742G- \> AR239QSquamous cell carcinoma1.07^[@CR179]^Breast cancer0.98/0.12^[@CR111],\ [@CR180]^Uterine carcinoma0.64^[@CR181]^Ovarian cancer1.01^[@CR182]^Colorectal adenoma1.09^[@CR183]^Liver cancer0.98^[@CR184]^595G- \> AG199S---716G- \> AQ239R---1218G- \> TQ406H---Cystathionine β-synthase (CBS)833T- \> CI278T---699C- \> TY233Y---1080C- \> TA360A---572C- \> TT191M---139C- \> TS466L---502G- \> AV168M---797G- \> AR266K---1150A- \> GK384E---341C- \> TA114V---919G- \> AG307S---TCN 2776 G \> CR259PColorectal adenoma0.753^[@CR183]^Colorectal cancer1.137^[@CR185]^Glioblastoma1.028^[@CR174]^Primary central nervous system lymphoma1.338^[@CR186]^Ovarian cancer1.389^[@CR182]^TYMSTS 3́-UTR---Esophageal cancer0.73^[@CR187]^---Stomach cancer1.12^[@CR187]^TSER---Breast cancer1.09^[@CR187]a^Papers that reported no association have been given the value of 1.00

There is no clear explanation for why the Hcy levels vary between early and late stage cancer. However, we speculate that cells in the early stage might not secrete Hcy, as it facilitates the proliferation process of cancer cells^[@CR48]^. Studies have shown that increased homocysteine levels lead to increased cellular proliferation in Caco-2 cell lines. This enhanced proliferation can be reversed by folate supplementation in the culture medium or by supplementation with its downstream metabolites, such as 5-MTHF^[@CR49]^. However, advanced-stage cancer cells might secrete Hcy because a very high Hcy concentration might also be cytotoxic to the cancer cells. Therefore, it may be important for proliferating cells to maintain an optimum Hcy concentration. This speculation, however, requires further experimental validation.

I (d) Cancer patients develop thromboembolisms due to Hcy toxicity {#Sec5}
==================================================================

One major symptom of hyperhomocysteinemia is the formation of venous thromboembolism (VTE). VTE is the most frequent complication and second most common cause of death among cancer patients^[@CR50]^. Advanced-stage cancer patients develop both hyperhomocysteinemia and VTE. Alternatively, in early cancer patients (without homocysteinuria), VTE is absent^[@CR51]^. Indeed, the advanced-stage cancer patients have a greater risk for developing VTE, with a frequency of 5--15%^[@CR51],[@CR52]^ (in comparison, the risk for the normal population is 0.1%). Postchemotherapy cancer patients (who are known to be at risk for homocystinuria) account for 13% of the total pool of VTE patients^[@CR53]^. In postsurgery patients, their susceptibilities to embolism and thrombosis are increased three-fold and two-fold, respectively^[@CR54]^. Use of central venous catheters and hormonal adjuvant therapy (e.g., Tamoxifen) also predisposes patients to VTE^[@CR51]^ due to increased plasma Hcy levels. Thus, there is a close link between cancer and Hcy-induced development of VTE.

The mechanism underlying the cancer-related thrombosis induced by elevated Hcy^[@CR55]^ is complex and not well understood. However, it has been thought to result from endothelial disturbances caused by the formation of Hcy-mediated free-radicals^[@CR56]^. Hcy is a pro-oxidant, and the formation of Hcy-Hcy dimers and Hcy-protein adducts that help to generate free radicals are well established. Hcy can also form a more highly reactive compound called homocysteine thiolactone. Homocysteine thiolactone has been known to form covalent adducts with lysine or arginine residues in proteins, resulting in the formation of insoluble toxic protein aggregates or amyloids^[@CR2],[@CR57],[@CR58]^. The deposition of such aggregates in the blood or heart may, therefore, impede normal heart function and physiology. Furthermore, modification of hemostatic proteins (via N-homocysteinylation or S-homocysteinylation) has also been reported to impede NO metabolism, which may cause biotoxicity in endothelial cells^[@CR59]^. Hcy also inhibits thrombomodulin and Protein C-dependent inactivation of Factor V~a~;^[@CR60]^ therefore, blood coagulation is enhanced in the presence of Hcy. Furthermore, Hcy limits the secretion of nitric oxide (NO), leading to increased platelet aggregation and decreased antithrombic activities in the endothelial cells^[@CR61],[@CR62]^.

I (e) Allelic polymorphisms in sulfur metabolism genes and associated risk of cancer {#Sec6}
====================================================================================

Various case control and cohort studies^[@CR63]--[@CR70]^ have shown that mutations and polymorphisms exist in genes involved in homocysteine metabolism (*MTHFR, CBS, MTRR, MTR, MTHFD, BHMT, TYMS, TCN 2*). Polymorphic alleles of these genes were found to be linked with neural tube defects^[@CR71]^ and/or vascular thromboembolism^[@CR72],[@CR73]^, which are symptoms of hyperhomocysteinemia. Recent studies have shown that these polymorphisms are also closely associated with different cancer types (Table [2](#Tab2){ref-type="table"}). For instance, *MTHFR* has \~6375 polymorphisms, consisting of 650 deletions, 05 multiple base substitutions, 140 repeat variations, and 5580 SNPs^[@CR74]^. Two common polymorphisms, a 677C- \> T transition at codon 222 (Ala222Val)^[@CR19],[@CR27],[@CR63],[@CR73],[@CR75]^ and a 1298A- \> C transversion at codon 429 (Glu429Ala)^[@CR75],[@CR76]^, have been reported to be associated with various cancer types, including endometrial carcinoma, esophageal squamous cell carcinoma (SCC), colon cancer, acute lymphocytic leukemia (ALL), and prostate cancer. In addition to 677C- \> T and 1298A- \> C, there is a third polymorphism, 1793G- \> A, whose frequency is very low (\~ 4.6% or less) and which is confined to colorectal cancer^[@CR77]^. The 677C- \> T polymorphism affects the protein's catalytic activity and the 1298A- \> C polymorphism affects its regulatory function^[@CR20],[@CR78]^. Homozygotes (677 CC, \~ 60%) are more frequent than heterozygotes (677 CT, \~ 31%), but this pattern is reversed in the case of 1298 (1298AC, \~ 53% and 1298AA, \~ 31%). The 677TT and 1298CC homozygotes were found to have reduced prostate cancer risk, as the frequencies are very low (9 and 11%, respectively)^[@CR21],[@CR79]^. The risk factor associated with the 677C- \> T polymorphism has been found to depend on the type of cancer, as it confers a higher risk for endometrial carcinoma^[@CR80]^(7), esophageal SCC^[@CR81]^, and prostate cancer^[@CR82]--[@CR84]^, while it has little or no effect on the risk for colon cancer^[@CR14],[@CR85],[@CR86]^ and acute lymphoid leukemia^[@CR87]^. The variable behavior of 677C- \> T in different cancer types indicates that the environment or genetic background might help to dictate the activity of the polymorphism. In this context^[@CR88]^, a number of factors have been proposed, including folate status, methionine, and the effects of alcohol consumption, to be the risk factor connecting the 677C- \> T polymorphism to colorectal cancer. Another possibility is that the 677C- \> T polymorphism is dominant negative in some cancer types but not in others based on the functional effect of the polymorphism.

*MTRR* has \~9461 polymorphisms, out of which 1051 are deletions, 01 are multiple base substitutions, 315 are repeat variations, and 8094 are SNPs^[@CR89]^. Out of this pool, only one polymorphism (*MTRR* A66G, Ile22Met)^[@CR14],[@CR18],[@CR90],[@CR91]^ has been studied and found to be associated with leukemia and colorectal cancer. This leukemic polymorphism has an allelic frequency of 51% in white populations^[@CR87],[@CR90]^ Comparison of the relationships between homozygosity and heterozygosity and colorectal cancer revealed that homozygotes (GG) have a three-fold higher risk compared with that of heterozygotes (AG)^[@CR14],[@CR92]^. Since the leukemic allelic frequency is very high in the white population, it is important to investigate other populations to determine if genetic background affects the frequencies or functions of polymorphic *MTRR*.

Similarly, *MTR* has \~26150 polymorphisms, out of which 2643 are deletions, 06 are multiple base substitutions, 221 are repeat variations, and 23245 are SNPs^[@CR105]^. One significant polymorphism (*MTR* A2756G; Asp919Gly) has been documented in *MTR*. This 2756A- \> G variant is associated with head, esophageal and neck squamous cell carcinoma, colorectal adenoma, colorectal carcinoma, lung cancer, multiple myeloma, cervical cancer, uterine cancer, and glioblastoma multiforme^[@CR18],[@CR24],[@CR37],[@CR93]--[@CR97]^. This polymorphism is associated with a decreased risk for colorectal cancer^[@CR14],[@CR90]^, and no correlation could be established between this *MTR* variant and the incidence of breast and upper gastrointestinal tract carcinomas^[@CR98],[@CR99]^, suggesting that the severity of the effect of the polymorphism might depend on the type of cancer.

*MTHFD-*1 has \~16991 polymorphisms, out of which 1913 are deletions, 07 are multiple base substitutions, 215 are repeat variations, and 14856 are SNPs^[@CR100]^. One polymorphism (1958G- \> A; Ala653Gly)^[@CR97],[@CR101],[@CR102]^ associated with acute lymphoid leukemia, which is located within the 10-formyl THF synthetase domain, has been reported^[@CR103]^. No links between *MTHFD* variants and lung cancer risk could be established (Liu, Jin et al. 2008). Another polymorphism, (401G- \> A; Arg134Lys), which is in the cyclohydrolase/dehydrogenase domain, was also reported by^[@CR102]^, but it is associated with a low colon cancer risk.

*TYMS* expression is a highly regulated process that is modulated by unique tandem repeat sequences and significant polymorphisms in the 5́-UTR of the thymidylate synthase enhancer region (TSER) and in the 3́-UTR (TS1494del6b) of the gene^[@CR104]^. *TYMS* has \~5892 polymorphisms, out of which 1078 are deletions, 05 are multiple base substitutions, 398 are repeat variations, and 4411 are SNPs^[@CR105]^. The TSER variant is most commonly present as double- (2R) and triple- (3R) repeat sequences, although 4R, 5R, and 9R repeats also exist. 3R sequences show higher translational efficiency than 2R sequences. Homozygous 3R/3R subjects show higher TYMS protein expression and higher enzyme activity^[@CR106]^. The second *TYMS* polymorphism identified is a 6 bp deletion/insertion at bp 1494 in the 3́-UTR of the *TYMS* gene. Several lines of evidence suggest that variation in the *TYMS* gene is associated with cancer risk. However, the risk factor associated with these polymorphisms depends on the type of cancer. In the cases of stomach, colorectal, and lung cancer, the TYMS enzyme activity and mRNA expression were found to be increased.

Transcobalamin II (TCN II) is a serum protein that transports vitamin B12 (cobalamin) from the ileum to other tissues. Vitamin B12 serves as an important molecule in the remethylation of methionine from Hcy and is important for the transformation of MTHF to THF. *TCN-2* has \~8291 polymorphisms, out of which 1183 are deletions, 02 are multiple base substitutions, 146 are repeat variations, and 6960 are SNPs^[@CR107]^. One common polymorphism in the *TCN 2* gene is a G to C substitution (776 G \> C, rs1801198) that results in replacement of a proline with an arginine^[@CR108]^ In a recent meta-analysis, it was shown that subjects with the rs1801198 GG genotype had significantly lower concentrations of holotranscobalamin and higher Hcy levels compared to subjects with the rs1801198 CC genotype. This polymorphism has also been shown to be associated with different cancers, including colorectal cancer, ovarian cancer, glioblastoma, among others. However, most of the cancer types did not have close association, as indicated by OR values near or equal to 1. Colorectal cancer, ovarian cancer, and central nervous system lymphoma, on the other hand, have higher OR values and, therefore, exhibit significant association (Table [2](#Tab2){ref-type="table"}). Therefore, it is thought that the *TCN 2* polymorphism rs1801198 significantly alters the circulating holotranscobalamin levels. Since TCN 2 plays a vital role in vitamin B12 metabolism, it is reasonable to suspect that the rs1801198 polymorphism may affect pathological conditions related to vitamin B12 deficiency.

*BHMT* has \~5271 polymorphisms, out of which 484 are deletions, 01 multiple base substitution, 140 are repeat variations, and 4648 are SNPs^[@CR109]^. Out of these variations, three significant mutations (Gly199Ser, Glu239Arg, and Glu406His) and one polymorphism have been examined. The polymorphism is the G to A substitution (742 G \> A, rs3733890), which replaces arginine by glutamine at codon 239. A study incorporating meta-analysis was performed to investigate the rs3733890 polymorphism and cancer susceptibility. It was shown that this polymorphism showed no statistically significant association with increased risk of various cancers, including head and squamous cell carcinoma, breast cancer, ovarian cancer, colorectal adenoma, and liver cancer. However, a negative association was observed in uterine cervical cancer (Table [2](#Tab2){ref-type="table"}).

*CBS* has \~6617 polymorphisms, out of which 573 are deletions, 04 are multiple base substitutions, 1059 are repeat variations, and 4981 are SNPs^[@CR110]^. Interestingly, none of these mutations have been shown to cause any significant predisposition towards any type of cancer^[@CR111]^. This observation opens an avenue for future research studies focusing on understanding and identifying the frequencies of *BHMT* and *CBS* genotypes and their associations with and prevalence in different cancer types.

I (f) CBS is associated with cancer *via* H~2~S production {#Sec7}
==========================================================

H~2~S, which is a signaling molecule, is substantially involved in vasorelaxation, acting as a neuromodulator^[@CR112],[@CR113]^. Recently, H~2~S has gained attention in cancer due to its cytotoxic and cytoprotective effects. It plays a key role in the bioenergetics of tumor cells and stimulates their proliferation, migration, and invasion^[@CR114]--[@CR116]^. In humans, CBS normally catalyzes the condensation of serine with homocysteine to produce cystathionine and water, a pivotal reaction in the trans-sulfuration pathway. In an alternative reaction, CBS can produce H~2~S *via* β-elimination and β-replacement^[@CR117]^ reactions. The β-elimination reaction involves catalysis of cysteine by CBS with corresponding H~2~S production, whereas in the β-replacement mechanism, the reaction between L-cysteine and 2-mercaptoethanol enables CBS to produce H~2~S. Various clinical studies have shown that there is *CBS* overexpression and, hence, increased H~2~S production, in many cancer types, including colon, ovarian, gastric, colorectal, prostate, gastroesophageal cancer, and endometrial cell angiogenesis^[@CR118]--[@CR121]^ (Fiorucci, Antonelli et al.;^[@CR118]^ Guo, Gai et al.;^[@CR119]^ Bhattacharyya, Saha et al.;^[@CR120]^ Szabo, Coletta et al. 2013; Modis, Coletta et al. 2014; Hellmich, Coletta et al.;^[@CR122]^ Katsouda, Bibli et al^[@CR121]^.). The role of H~2~S in cancer has been elucidated. It is known to enhance tumor growth and increase cellular proliferation by (i) stimulating cellular bioenergetics, (ii) activating proliferative, migratory, and invasive signaling pathways, and (iii) enhancing angiogenesis in tumors^[@CR122]^. Other studies have demonstrated that HCT116 cells (a transformed cell line) have CBS upregulation and enhanced H~2~S production compared to nontransformed cells^[@CR123]^.

ShRNA-mediated silencing of *CBS* or suppression of its activity by pharmacological means (using aminooxyacetic acid)^[@CR124]^ results in reduced mitochondrial function (ATP turnover, respiratory reserve capacity, and oxygen consumption) and impaired glycolysis^[@CR112]^. A clinical study of colon cancer showed reduced angiogenesis and increased growth in xenografts derived from colon cancer patients incubated in mice treated with aminooxyacetic acid^[@CR125]^. Alternatively, H~2~S production induces angiogenesis in various experimental models^[@CR114]^. In another development^[@CR126]^, investigated the effects of S-adenosyl-L-methionine (SAM) on tumor bioenergetics^[@CR127],[@CR128]^. SAM is an allosteric activator of CBS that binds to the regulatory domain of *CBS*. The study revealed that SAM enhances H~2~S production of in the HCT116 cancer cell line. Mechanistically, it is not completely known how H~2~S helps to stimulate tumor growth^[@CR129]^. However, it has been argued that H~2~S serves as an autocrine stimulator during tumor proliferation. Therefore, modulation of the CBS and H~2~S levels could help limit cancer proliferation and promote its reversal.

Conclusion {#Sec8}
==========

It is clear from this review that there are compelling genetic, epigenetic and environmental factors that establish a close association between disturbed Hcy metabolism and cancer. Therefore, Hcy-elevating drugs should be restrictively prescribed to cancer patients, and clinicians should closely monitor Hcy levels after chemotherapy or surgery. To date, the effects of Hcy on the growth and proliferation of tumor cells remain poorly understood. Insight into the effects of Hcy on the growth and proliferation of cancer cells would yield novel, promising strategies to curb cancer. Nevertheless, Hcy can be used as a potential tumor biomarker for a variety of cancers.

**Publisher's note:** Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

The authors declare that they have no conflict.
